Separate GHK-Cu penetration experiments from human treatment evidence, understand product-specific findings, and assess delivery claims.
More peptide crossing a skin sample does not establish better-looking skin, safe repeated use or an effective home routine. The GHK-Cu delivery research reviewed here cannot justify applying research peptides to freshly microneedled skin. The relevant questions are what was tested, in whom, and which outcome improved.
The 2015 copper-peptide delivery paper used excised rat skin and human skin from a cadaver in laboratory diffusion experiments. A polymer microneedle array increased measured peptide and copper passage under the tested conditions. Copper and peptide were measured separately, so the results should not be treated as a direct measurement of intact GHK-Cu reaching living facial fibroblasts.
The safety work used cultured cells and pigs, including short observation after application. The authors explicitly said human safety still needed confirmation. This was not a trial measuring wrinkles, scars or long-term adverse effects in people.
The distinction matters: demonstrating delivery answers a formulation question. It does not tell a consumer whether the delivered amount is beneficial, which commercial serum is equivalent, or whether a repeated procedure is safe.
A 2025 randomized, double-blind split-face study tested an angiopoietin-derived QHREDGS peptide regimen after fractional radiofrequency microneedling in eight people. The comparison used a peptide-free control. The original abstract reports better early recovery measures and preferences for the peptide regimen, with assessments around two and seven days and no reported adverse events.
That is a small, short study of a different peptide and specified products. It does not demonstrate that GHK-Cu, BPC-157 or an arbitrary cosmetic serum has the same effects. Nor does it establish long-term collagen improvement or rule out uncommon complications. The full paper was unavailable in this review, so formulation and conflict-of-interest details could not be independently assessed from the abstract.
A statement that no peptide has ever been studied after needling would be too broad. A claim that this study validates any peptide after any device would also be wrong.
The FDA states that microneedling devices are not approved to deliver cosmetics, topical medicines, vitamin solutions or blood products into skin. Its assessment of a device's specified use cannot be transferred to an added serum. Lack of that authorization is not proof that every combination is ineffective; it means the combination needs its own evidence and risk assessment.
Research-only powders and vials should not be treated as established human skin treatments. FDA's compounding safety information identifies concerns about BPC-157, including immune reactions and peptide impurities. Its GHK-Cu entry concerns injectable routes specifically; it should not be misrepresented as a finding about every intact-skin cosmetic serum.
Before treating words such as “liposomal,” “encapsulated” or “enhanced penetration” as a reason to buy, ask for evidence on the finished product:
An ingredient list and a higher price cannot answer those questions. Likewise, a favorable result for one delivery system does not establish that adding solvents or puncturing skin at home improves a different product.
For an actual procedure, get product and aftercare instructions from the treating clinician. Avoid improvising a peptide mixture or application window from a permeability graph. Our skin microneedling evidence guide covers the procedure questions; the human-evidence checklist explains how to examine a treatment claim. Neither a delivery experiment nor a purity certificate supplies missing human safety and benefit evidence.
Powered by BTST